Ventyx Biosciences
VTYX
VTYX was delisted on the 3rd of March, 2026.
138 hedge funds and large institutions have $1.9B invested in Ventyx Biosciences in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 23 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 44
10% more capital invested
Capital invested by funds: $1.73B → $1.9B (+$169M)
2.78% more ownership
Funds ownership: 89.91% → 92.69% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less call options, than puts
Call options by funds: $9.34M | Put options by funds: $10.3M
8% less funds holding
Funds holding: 150 → 138 (-12)
43% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.3M |
| 3 |
BlackRock
New York
|
+$13.9M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
+$11.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.3M |
| 2 |
DM
Deerfield Management
New York
|
-$20.2M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$11.7M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$8.23M |
| 5 |
Morgan Stanley
New York
|
-$7.96M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SEC
151
Seven Eight Capital
New York
| – | -$301K | -9,184 | Closed |
|
|
MWM
152
Moran Wealth Management
Naples,
Florida
| – | -$273K | -8,312 | Closed |
|
|
SO
153
STRS Ohio
Columbus,
Ohio
| – | -$268K | -8,200 | Closed |
|
154
Two Sigma Advisers
New York
| – | -$269K | -8,200 | Closed |
|
|
PCM
155
Prelude Capital Management
New York
| – | -$254K | -7,746 | Closed |
|
|
NC
156
NinePointTwo Capital
Los Angeles,
California
| – | -$253K | -7,741 | Closed |
|
|
ECM
157
ExodusPoint Capital Management
New York
| – | -$229K | -6,994 | Closed |
|
|
CSS
158
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$137K | -4,179 | Closed |
|
|
TWC
159
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$42.3K | -1,060 | Closed |
|
160
Allspring Global Investments
Charlotte,
North Carolina
| – | -$15K | -456 | Closed |
|
|
C
161
Covestor
London,
United Kingdom
| – | -$35 | -1 | -20% |
|
VTYX Hedge Fund Activity: Q3 2023 in Review
138 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2023, worth a combined $1.9B — up 9.8% from $1.73B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of VTYX and 13 opened new positions — a net loss of 10 holders — while 44 trimmed existing stakes and 61 added.
The largest buyer was Adage Capital Partners, adding an estimated $30.9M. The largest seller was Lord, Abbett & Co, cutting an estimated $20.3M.
- 138 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2023, down from 150 in Q2 2023.
- Funds reported $1.9B of Ventyx Biosciences stock for Q3 2023, up 9.8% quarter-over-quarter.
- 13 funds opened new Ventyx Biosciences positions in Q3 2023 and 23 closed out, a net change of -10 holders.
- The largest Ventyx Biosciences buyer in Q3 2023 was Adage Capital Partners, an estimated $30.9M added.
- The largest Ventyx Biosciences seller in Q3 2023 was Lord, Abbett & Co, an estimated $20.3M sold.
Based on aggregated 13F filings for Q3 2023.